Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

Although inotersen met efficacy endpoints in Phase III familial amyloidosis study, adverse event rates raised a red flag and give Alnylam's competing patisiran an edge on safety, at least for now.